# Duncan Bruce McLaren

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7115060/publications.pdf

Version: 2024-02-01

| 55 | 3,932 | 318942 | 252626 |
|---|---|---|---|
| papers | citations | 23 h-index | 46 g-index |

| 56 | 56 | 56 | 5731 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet, The, 2022, 399, 447-460. | 6.3 | 173 |
| 2 | Response to letter to the editor of radiotherapy and oncology regarding the paper entitled â€œ50 years of radiotherapy research: Evolution, trends and lessons for the futureâ€œ by Berger et al. (December) Tj ETQq0 0 0 rgBT /Overlock 10 Tf | | 0 |
| 3 | Fast and automated biomarker detection in breath samples with machine learning. PLoS ONE, 2022, 17, e0265399. | 1.1 | 3 |
| 4 | Peppermint protocol: first results for gas chromatography-ion mobility spectrometry. Journal of Breath Research, 2022, 16, 036004. | 1.5 | 4 |
| 5 | Localised 3D disparity regularisation for improving contour propagation in Adaptive Radiotherapy. , 2021, , . | | 1 |
| 6 | Tissue- and Liquid-Based Biomarkers in Prostate Cancer Precision Medicine. Journal of Personalized Medicine, 2021, 11, 664. | 1.1 | 11 |
| 7 | 50Âyears of radiotherapy research: Evolution, trends and lessons for the future. Radiotherapy and Oncology, 2021, 165, 75-86. | 0.3 | 12 |
| 8 | Breath markers for therapeutic radiation. Journal of Breath Research, 2021, 15, 016004. | 1.5 | 5 |
| 9 | Radiological Response Heterogeneity Is of Prognostic Significance in Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-targeted Therapy. European Urology Focus, 2020, 6, 999-1005. | 1.6 | 5 |
| 10 | VOCCluster: Untargeted Metabolomics Feature Clustering Approach for Clinical Breath Gas Chromatography/Mass Spectrometry Data. Analytical Chemistry, 2020, 92, 2937-2945. | 3.2 | 26 |
| 11 | Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncology, The, 2020, 21, 162-174. | 5.1 | 450 |
| 12 | Protocol for tumour-focused dose-escalated adaptive radiotherapy for the radical treatment of bladder cancer in a multicentre phase II randomised controlled trial (RAIDER): radiotherapy planning and delivery guidance. BMJ Open, 2020, 10, e041005. | 0.8 | 16 |
| 13 | <scp>EPID</scp>â€based inÂvivo dosimetry using Dosimetry Checkâ„¢: Overview and clinical experience in a 5â€yr study including breast, lung, prostate, and head and neck cancer patients. Journal of Applied Clinical Medical Physics, 2019, 20, 6-16. | 0.8 | 44 |
| 14 | Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Annals of Oncology, 2018, 29, 1235-1248. | 0.6 | 196 |
| 15 | Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness. European Urology Oncology, 2018, 1, 449-458. | 2.6 | 19 |
| 16 | Convolutional neural networks for automated targeted analysis of raw gas chromatography-mass spectrometry data. , 2018, , . | | 11 |
| 17 | Costâ€effectiveness of zoledronic acid and strontiumâ€89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrateâ€refractory prostate cancer: results from the <scp>TRAPEZE</scp> trial (<scp>ISRCTN</scp> 12808747). BJU International, 2017, 119, 522-529. | 1.3 | 18 |
| 18 | Clinical and patientâ€reported outcomes of <scp>SPARE</scp> â€“ a randomised feasibility study of selective bladder preservation versus radical cystectomy. BJU International, 2017, 120, 639-650. | 1.3 | 105 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Can dynamic changes in prognostic markers predict survival in patients receiving VEGF-targeted therapy in clear cell renal cell carcinoma?. Journal of Clinical Oncology, 2017, 35, e16061-e16061. | 0.8 | 0 |
| 20 | Targeted SERS nanosensors measure physicochemical gradients and free energy changes in live 3D tumor spheroids. Nanoscale, 2016, 8, 16710-16718. | 2.8 | 23 |
| 21 | INVITED REVIEWâ€"IMAGE REGISTRATION IN VETERINARY RADIATION ONCOLOGY: INDICATIONS, IMPLICATIONS, AND FUTURE ADVANCES. Veterinary Radiology and Ultrasound, 2016, 57, 113-123. | 0.4 | 8 |
| 22 | Measuring the effects of fractionated radiation therapy in a 3D prostate cancer model system using SERS nanosensors. Analyst, The, 2016, 141, 5056-5061. | 1.7 | 14 |
| 23 | Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both. JAMA Oncology, 2016, 2, 493. | 3.4 | 78 |
| 24 | A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK). Annals of Oncology, 2016, 27, 880-886. | 0.6 | 15 |
| 25 | Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet, The, 2016, 387, 1163-1177. | 6.3 | 1,570 |
| 26 | TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer. Health Technology Assessment, 2016, 20, 1-288. | 1.3 | 29 |
| 27 | Identifying radiotherapy target volumes in brain cancer by image analysis. Healthcare Technology Letters, 2015, 2, 123-128. | 1.9 | 5 |
| 28 | Cyborgs in the Everyday: Masculinity and Biosensing Prostate Cancer. Science As Culture, 2015, 24, 484-506. | 2.4 | 31 |
| 29 | The Importance of Prostate-specific Antigen (PSA) Nadir and Early Identification of PSA Relapse after 10 Years of Prostate Iodine125 Seed Brachytherapy in Edinburgh. Clinical Oncology, 2015, 27, 519-526. | 0.6 | 7 |
| 30 | Translational research will fail without surgical leadership: SCOTRRCC a successful surgeon-led Nationwide translational research infrastructure in renal cancer. Journal of the Royal College of Surgeons of Edinburgh, 2015, 13, 181-186. | 0.8 | 3 |
| 31 | Survival with Newly Diagnosed Metastatic Prostate Cancer in the â€œDocetaxel Eraâ€: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). European Urology, 2015, 67, 1028-1038. | 0.9 | 340 |
| 32 | Identifying the dominant prostate cancer focal lesion using image analysis and planning of a simultaneous integrated stereotactic boost. Acta OncolÃ³gica, 2015, 54, 1543-1550. | 0.8 | 11 |
| 33 | Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer. (ISRCTN 12808747) TRAPEZE.. Journal of Clinical Oncology, 2015, 33, e16108-e16108. | 0.8 | 2 |
| 34 | Active shape models with optimised texture features for radiotherapy. Proceedings of SPIE, 2014, , . | 0.8 | 0 |
| 35 | Clinically relevant fatigue in recurrence-free prostate cancer survivors. Annals of Oncology, 2012, 23, 65-72. | 0.6 | 68 |
| 36 | Clinically relevant fatigue in men with hormone-sensitive prostate cancer on long-term androgen deprivation therapy. Annals of Oncology, 2012, 23, 1542-1549. | 0.6 | 64 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Cytoreductive Nephrectomy Preceding Adjuvant Immunotherapy for Metastatic Renal Cell Carcinoma: 8 Years' Experience in a UK Tertiary Referral Centre. British Journal of Medical and Surgical Urology, 2011, 4, 101-107. | 0.2 | 0 |
| 38 | DNA strand breaks and hypoxia response inhibition mediate the radiosensitisation effect of nitric oxide donors on prostate cancer under varying oxygen conditions. Biochemical Pharmacology, 2011, 81, 203-210. | 2.0 | 37 |
| 39 | The relevance of a hypoxic tumour microenvironment in prostate cancer. BJU International, 2010, 105, 8-13. | 1.3 | 94 |
| 40 | Non-surgical treatment for early prostate cancer. Journal of the Royal College of Physicians of Edinburgh, The, 2010, 40, 340-342. | 0.2 | 3 |
| 41 | Characterisation of radiotherapy planning volumes using textural analysis. Acta OncolÃ³gica, 2008, 47, 1303-1308. | 0.8 | 12 |
| 42 | Texture analysis of 3D bladder cancer CT images for improving radiotherapy planning. , 2008, , . | | 2 |
| 43 | Late Relapse and Follow-up Protocols in Testicular Germ Cell Tumours: The Edinburgh Cancer Centre Experience and Review of the Literature. Clinical Medicine Oncology, 2008, 2, CMO.S321. | 0.2 | 1 |
| 44 | Image-guided radiotherapy of bladder cancer: Bladder volume variation and its relation to margins. Radiotherapy and Oncology, 2007, 84, 307-313. | 0.3 | 36 |
| 45 | A long and winding road: the role of chemotherapy for hormone-refractory prostate cancer. International Journal of Clinical Practice, 2007, 61, 1964-1965. | 0.8 | 0 |
| 46 | A concomitant tumour boost in bladder irradiation: Patient suitability and the potential of intensity-modulated radiotherapy. Radiotherapy and Oncology, 2006, 80, 98-105. | 0.3 | 13 |
| 47 | Outcome analysis of 300 prostate cancer patients treated with neoadjuvant androgen deprivation and hypofractionated radiotherapy. International Journal of Radiation Oncology Biology Physics, 2006, 65, 982-989. | 0.4 | 32 |
| 48 | Testicular Sex Cordâ€“Stromal Tumours: The Edinburgh Experience 1988â€“2002, and a Review of the Literature. Clinical Oncology, 2005, 17, 322-327. | 0.6 | 52 |
| 49 | Neoadjuvant Chemotherapy in Transitional-cell Carcinoma of the Bladder. Clinical Oncology, 2005, 17, 503-507. | 0.6 | 7 |
| 50 | Treatment margins and treatment fractionation in conformal radiotherapy of muscle-invading urinary bladder cancer. Radiotherapy and Oncology, 2004, 71, 65-71. | 0.3 | 15 |
| 51 | Radical Radiotherapy and Salvage Cystectomy as the Primary Management of Transitional Cell Carcinoma of the Bladder. Results Following the Introduction of a CT Planning Technique. Clinical Oncology, 2002, 14, 141-147. | 0.6 | 31 |
| 52 | The Comet Assay in Clinical Practice. Acta OncolÃ³gica, 1999, 38, 839-844. | 0.8 | 50 |
| 53 | Watchful waiting or watchful progression?. , 1998, 82, 342-348. | | 87 |
| 54 | Impact of nicotinamide on human tumour hypoxic fraction measured using the comet assay. Radiotherapy and Oncology, 1997, 45, 175-182. | 0.3 | 25 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Hypofractionated radiotherapy for muscle invasive bladder cancer in the elderly. Radiotherapy and Oncology, 1997, 43, 171-174. | 0.3 | 68 |